Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

• Published in: npj vaccines Vol. 7; no. 1; pp. 85 - 13
• Main Authors: Tioni, Mariana F., Jordan, Robert, Pena, Angie Silva, Garg, Aditya, Wu, Danlu, Phan, Shannon I., Weiss, Christopher M., Cheng, Xing, Greenhouse, Jack, Orekov, Tatyana, Valentin, Daniel, Kar, Swagata, Pessaint, Laurent, Andersen, Hanne, Stobart, Christopher C., Bloodworth, Melissa H., Stokes Peebles, R., Liu, Yang, Xie, Xuping, Shi, Pei-Yong, Moore, Martin L., Tang, Roderick S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.07.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250/590/1867; 631/326/596/4130; Antibodies; Biomedical and Life Sciences; Biomedicine; Clinical trials; Coronaviruses; COVID-19; COVID-19 vaccines; Glycoproteins; Immunoglobulins; Infections; Infectious Diseases; Medical Microbiology; Medicine; Neutralization; Pandemics; Pathogens; Proteins; Public Health; Respiratory syncytial virus; Severe acute respiratory syndrome coronavirus 2; Vaccine; Vaccines; Virology; Viruses

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a li...